Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RAD52 | P43351 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15720288 | 0.98 | CYP1A2 (0.40) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| SCHEMBL15739274 | 0.96 | CYP1A2 (0.38) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL17158327 | 0.94 | KCNH3 (0.38) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| SCHEMBL17158318 | 0.85 | CYP1A2 (0.39) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL17158312 | 0.84 | KCNH3 (0.38) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| SCHEMBL9106534 | 0.82 | CYP1A2 (0.46) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| SCHEMBL17158230 | 0.81 | CYP1A2 (0.38) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| SCHEMBL15720421 | 0.81 | CYP1A2 (0.43) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL17158285 | 0.80 | CYP1A2 (0.38) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| SCHEMBL17158215 | 0.79 | CYP1A2 (0.42) | CYP1A2CYP2C19GAAL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | claimed |
| US-20250325554-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS | ENALARE THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2023225177-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS | ENALARE THERAPEUTICS INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
| EP-2920155-A2 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | Galleon Pharmaceuticals, Inc. (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014078575-A2 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325554-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS | NDUFB6, NDUFB7, CHRM5 | CYP1A2 895/4885CYP2C19 801/4885GAA 804/4885 |
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | MTNR1B, TNNC1, PER2 | CYP1A2 531/4885CYP2C19 648/4885GAA 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.